| 1. |
Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis, 2019, 69(Supplement_7): S521-S528.
|
| 2. |
Mohamed A, Daef E, Nafie A, et al. Characteristics of carbapenem-resistant Gram-negative bacilli in patients with ventilator-associated pneumonia. Antibiotics (Basel), 2021, 10(11): 1325.
|
| 3. |
Temkin E, Adler A, Lerner A, et al. Carbapenem-resistant enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci, 2014, 1323(1): 22-42.
|
| 4. |
王明貴. 廣泛耐藥革蘭陰性菌感染的實驗診斷、抗菌治療及醫院感染控制: 中國專家共識. 中國感染與化療雜志, 2017, 17(1): 82-92.
|
| 5. |
劉又寧. 碳青霉烯耐藥革蘭陰性菌感染的治療策略與困惑. 中華結核和呼吸雜志, 2019, 42(3): 161-163.
|
| 6. |
侯嘉, 邱潔, 鄭西衛, 等. 呼吸內科病房常見革蘭陰性桿菌的構成及耐藥性分析. 中國呼吸與危重監護雜志, 2010, 9(1): 83-85.
|
| 7. |
Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the united states predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis, 2017, 4(3): ofx176.
|
| 8. |
Zhang YW, Wang Q, Yin YY, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother, 2017, 62(2): e01882-17.
|
| 9. |
Kim T, Lee EJ, Park SY, et al. Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment. Medicine (Baltimore), 2018, 97(43): e12984.
|
| 10. |
譚莉, 曾莉怡, 吳健, 等. 老年患者耐碳青霉烯類鮑曼不動桿菌感染的耐藥性及預后影響因素分析. 中國實用醫刊, 2021, 48(1): 21-24.
|
| 11. |
Poulakou G, Lagou S, Karageorgopoulos DE, et al. New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Ann Transl Med, 2018, 6(21): 423.
|
| 12. |
中國碳青霉烯耐藥腸桿菌科細菌感染診治與防控專家共識編寫組, 中國醫藥教育協會感染疾病專業委員會, 中華醫學會細菌感染與耐藥防控專業委員會. 中國碳青霉烯耐藥腸桿菌科細菌感染診治與防控專家共識. 中華醫學雜志, 2021, 101(36): 2850-2860.
|
| 13. |
黃邵軍, 袁珊珊, 成聰聰. 重癥醫學科鮑曼不動桿菌的耐藥性及感染相關危險因素分析. 中國公共衛生管理, 2020, 36(6): 856-858.
|
| 14. |
Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections. Open Forum Infect Dis, 2019, 6(12): ofz522.
|
| 15. |
Rodríguez-Ba?o J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev, 2018, 31(2): e00079-17.
|
| 16. |
Igbinosa O, Dogho P, Osadiaye N. Carbapenem-resistant enterobacteriaceae: a retrospective review of treatment and outcomes in a long-term acute care hospital. Am J Infect Control, 2020, 48(1): 7-12.
|
| 17. |
袁瑾懿, 林東昉. 美國感染病學會對產超廣譜β內酰胺酶腸桿菌目細菌、碳青霉烯類耐藥腸桿菌目細菌和難治性耐藥銅綠假單胞菌的治療指導原則. 中國感染與化療雜志, 2021, 21(5): 633-638.
|
| 18. |
Baraldi E, Lindahl O, Savic M, et al. Antibiotic pipeline coordinators. J Law Med Ethics, 2018, 46(S1): 25-31.
|
| 19. |
Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect, 2022, 28(4): 521-547.
|